About Topical Innovations

When patients are in pain, all they want is relief from that pain. Topical Innovations (TI) is committed to help these patients and provide effective and safe therapies for a number of chronic pain syndromes:
• Neuropathic pain
• Neurogenic inflammation and Complex Regional Pain Syndrome (CRPS)
• Vulvodynia

Topical Innovations is dedicated to research and development of new topical analgesics that meet the needs of patients and their pain physicians and practitioners.

In 2015 first development steps were initiated in the field of the topical use of phenytoin containing formulations based on a proprietary platform of two patents. Since that time, TI pursues the development of various creams containing phenytoin and (co-)analgesics in various formulations.

Proof of Principle for phenytoin 10% cream in peripheral neuropathic pain

In 2018 TI completed a single-blind phase IIa, and generated positive proof of principle, based on data of 21 patients, published in ‘Pharmaceuticals’ a PubMed indexed journal. Furthermore, a number of innovative N-of-1 double blind cross-over reports were published, as well as a safety datapool of 70 patients.

Therefore, the main focus of TI is the repositioning of phenytoin as a topical analgesic for neuropathic pain.
TI currently looks for a partner for the worldwide development, marketing and sales of the phenytoin-based formulations.

Our slogan is: ‘Free of pain without side effects’.

Neuropathic pain afflicts millions of people in the world and accounts for over hundreds of billion euro of annual healthcare expenditures. Unfortunately, more than half of all the patients with suffering from neuropathic pain stop taking their pain medication, most probably due to insufficient effects or due to troublesome side effects. Therefore, new developments like topical analgesic creams are very much needed.

The first targeted indication is Painful Diabetic Neuropathy. Cooperation on the level of clinical phase III studies are ongoing with the Universities of Utrecht and Amsterdam. In the of summer 2018 the Dutch Medicines Evaluation Board (MEB), has advised a short development program for the marketing registration of phenytoin for the treatment of peripheral neuropathic pain. In the beginning of 2019 the European Patent Office found that the two patents are novel and inventive: 1) topical phenytoin for use in the treatment of peripheral neuropathic pain and 2) Topical pharmaceutical composition containing phenytoin and a (co-)analgesic for the treatment of chronic pain. Now TI is looking for a partner to devellop phenytoin cream for the treatment of peripheral neuropathic pain.